Get started
Author

Diyuan Xue

A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors
2022 · Diyuan Xue, Benjamin Moon, et al. · Science Immunology · 132
Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity
2021 · Jingya Guo, Yong Liang, et al. · Cell Research · 94
PDF
Next-generation cytokines for cancer immunotherapy
2021 · Diyuan Xue, Eric Hsu, et al. · Antibody Therapeutics · 86
PDF
An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery
2022 · Jiao Shen, Zhuangzhi Zou, et al. · The Journal of Experimental Medicine · 54
Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8+T cells for systemic antitumor responses
2024 · Zhuangzhi Zou, Jiao Shen, et al. · Nature Communications · 38
Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression
2017 · Jing Liao, Yan Luan, et al. · Cancer Immunology Research · 13
T Cell-Derived Lymphotoxin Is Essential for the Anti-Herpes Simplex Virus 1 Humoral Immune Response
2018 · Kaiting Yang, Yong Liang, et al. · Journal of Virology · 8
Dual targeting OX40 and IL-2 receptor enhances antitumor activity through tumor-infiltrating Treg depletion and CD8 + T-cell proliferation
2025 · Shuaishuai Cao, Zhichen Sun, et al. · Journal for ImmunoTherapy of Cancer · 6
PDF
Supplementary Figures and Protein Gene Sequences from Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression
2023 · Jing Liao, Yan Luan, et al.
Data from Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression
2023 · Jing Liao, Yan Luan, et al.
Data from Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression
2023 · Jing Liao, Yan Luan, et al.
Works count: 11
Citation count: 431
H-index: 7
I10-index: 6
Year
Topic
Type